Ozempic and Heart Disease: SELECT Trial Data & Cardiovascular Protection

The SELECT trial shows semaglutide reduces heart attacks and strokes by 20% in people with obesity. Combined with SUSTAIN 6 data (26% reduction in diabetics), semaglutide is one of the most cardioprotective medications available.

The SELECT Trial: Heart Protection in Non-Diabetics

The SELECT trial is the landmark 2023 study demonstrating semaglutide's cardiovascular benefits in people without diabetes.

Study design:

• Participants: 17,604 adults with obesity (BMI ≥ 27) or overweight with cardiovascular disease
• No diabetes requirement (unlike SUSTAIN 6)
• Semaglutide dose: 2.4 mg weekly
• Comparator: Placebo
• Duration: 5 years (2018–2023)
• Follow-up: Continued beyond trial (median 4.6 years of follow-up)

Primary outcome: Major adverse cardiovascular events (MACE) = heart attack, stroke, cardiovascular death

SELECT Trial Results: 20% Cardiovascular Risk Reduction

Key takeaways:

• Semaglutide reduced MACE by 20% overall
• Heart attacks specifically reduced by 38% — dramatic protection
• Strokes reduced by 27%
• Benefits in non-diabetics, proving cardiovascular benefit independent of diabetes
• Results consistent across subgroups (age, gender, baseline risk)

SUSTAIN 6 Trial: Cardiovascular Protection in Diabetics

While SELECT focused on non-diabetics, SUSTAIN 6 (published 2016) demonstrated semaglutide's cardiovascular benefits in type 2 diabetes.

Key results:

• MACE reduced by 26% in diabetics
• Heart attacks reduced by 26%
• Strokes reduced by 39%
• Cardiovascular death reduced by 26%
• 3-year follow-up (longer than SELECT)

Significance: SUSTAIN 6 was the first GLP-1 trial to show cardiovascular mortality reduction, establishing semaglutide as cardioprotective.

How Does Semaglutide Protect the Heart?

Multiple mechanisms contribute to cardiovascular benefit:

1. Weight Loss

SELECT participants lost 18% body weight (average 47 lbs). Weight loss reduces cardiovascular stress, improves blood pressure, and improves metabolic health. Weight loss alone contributes significantly to CVD protection.

2. Blood Pressure Reduction

Semaglutide reduces systolic blood pressure by 3–5 mmHg on average. Blood pressure is a major cardiovascular risk factor; even modest reduction prevents strokes and heart attacks.

3. Improved Blood Sugar Control

In diabetics, semaglutide reduces A1C by 1.5–1.8%. Improved glucose control reduces atherosclerosis progression. In non-diabetics, better metabolic health may prevent diabetes development.

4. Anti-Inflammatory Effects

Inflammation is a major driver of atherosclerosis. Semaglutide reduces inflammatory markers (CRP, IL-6, TNF-alpha), reducing plaque formation and rupture risk.

5. Lipid Improvement

Semaglutide improves cholesterol profiles: modest reduction in LDL ("bad") cholesterol, small increases in HDL ("good") cholesterol.

6. Improved Endothelial Function

The endothelium (inner lining of blood vessels) regulates blood flow and prevents clotting. Semaglutide improves endothelial function, reducing thrombotic risk.

7. Reduced Arterial Stiffness

Arteries become stiff with age and disease. Semaglutide reduces arterial stiffness, improving blood flow and reducing strain on the heart.

8. Direct Cardiac Effects

GLP-1 receptors are expressed in heart muscle. Direct GLP-1 signaling may improve heart function and reduce heart failure risk.

Semaglutide and Heart Failure: What You Need to Know

Heart failure is a potential concern with GLP-1s. Data are mixed:

SUSTAIN 6 findings: No significant heart failure worsening. Hospitalization for heart failure was numerically lower (not statistically significant).

SELECT trial findings: Heart failure hospitalization slightly increased, though absolute rates were low. Interpretation: mixed signal; benefit/risk still appears favorable.

Clinical practice: Most cardiologists feel that cardiovascular benefits outweigh heart failure concerns. However, if you have heart failure with reduced ejection fraction (HFrEF), discuss with your cardiologist before starting semaglutide.

Bottom line: For most heart disease patients, semaglutide is beneficial. Heart failure patients require individualized assessment with their cardiologist.

Heart Disease Populations That Benefit From Semaglutide

Diabetics With Established Coronary Artery Disease (CAD)

SUSTAIN 6 specifically enrolled people with CAD. Semaglutide is highly beneficial, reducing MACE by 26%. Recommended as part of secondary prevention.

Diabetics With History of Heart Attack or Stroke

Similar to CAD patients. Semaglutide reduces recurrent events by 26%. Should be considered standard therapy.

Non-Diabetics With Obesity and Heart Disease

SELECT showed 20% MACE reduction. Semaglutide is beneficial for weight loss and cardiovascular protection.

People at High Cardiovascular Risk

Those with multiple risk factors (hypertension, high cholesterol, smoking history) benefit from semaglutide's comprehensive cardiovascular protection.

Blood Pressure Benefits

Systolic blood pressure reduction: 3–5 mmHg average.

Clinical significance: Every 5 mmHg reduction in systolic BP prevents ~10% of cardiovascular events. Semaglutide's blood pressure benefit contributes meaningfully to CVD protection.

Important: If you're on blood pressure medications, your doctor may need to reduce doses as semaglutide lowers blood pressure. Don't adjust medications yourself; have your doctor monitor.

Combining Semaglutide With Heart Medications

Semaglutide combines safely with standard heart medications: